drugset / Trial / NCT00417716
Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Intravitreal Bevacizumab is an effective treatment for the diffuse diabetic macular edema
Timeline
- Start
- 2005-09
- Primary completion
- 2005-09
- Completion
- 2006-05
Outcome
Outcome not reported
Stopped (Enrollment): “Poor accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 2.5 mg | Intravitreal |